Serán Bioscience has secured an undisclosed growth investment led by Biospring Partners, with continued participation from existing investors Vivo Capital and Bain Capital Life Sciences, as well as members of the company’s executive leadership. The financing was announced on September 29, 2026.
The Bend, Oregon-based contract development and manufacturing organization plans to use the capital to expand its clinical-to-commercial capabilities and manufacturing infrastructure. A central part of the expansion is a new commercial manufacturing facility in Bend that is scheduled for completion in the third quarter of 2027. The site is designed to support commercial-scale particle engineering, including spray drying and nano-milling, along with finished-dose manufacturing capabilities such as granulation, tableting, coating, encapsulation and specialized powder filling.
Founded in 2016, Serán provides drug development, analytical and manufacturing services to pharmaceutical and biotechnology companies. Its capabilities include formulation development, dosage-form development, particle engineering, spray drying, cGMP manufacturing and analytical and quality-control services. The company is led by co-founder and CEO Dan Smithey.
The latest financing follows a strategic growth transaction of more than $200 million announced in September 2024. That transaction was led by Bain Capital Life Sciences, with Vivo Capital continuing as an investor, and was intended to support Serán’s expansion into commercial-scale manufacturing.
The new investment brings Biospring Partners into Serán’s investor group as the company continues developing its commercial manufacturing operations in Bend. Serán said the expansion is intended to extend its services from early drug development through commercial supply.
